Global Targeted DNA/RNA Sequencing market cagr 9.3%

Page 1

Targeted DNA/RNA Sequencing Market

Targeted DNA/RNA Sequencing Market Scope:

Industry Analysis, Market Size, Growth, Trends Till 2031

Request Sample Report

Targeted DNA/RNA Sequencing Market Size and Growth

The Targeted DNA/RNA Sequencing market research reports indicate a growing market size due to advancements in technology and increased demand for personalized medicine. The market is expected to reach a value of $8.5 billion by 2025, driven by the rising prevalence of cancer and genetic disorders. Request Sample Report

Companies Covered (Covid 19 Impact Covered)

◍ Illumina, Inc.

◍ F. Hoffmann-La Roche Ltd

◍ Agilent Technologies

◍ GATC Biotech Ag

◍ Oxford Nanopore Technologies

◍ Thermo Fisher Scientific, Inc.

◍ DNASTAR Inc.

◍ QIAGEN

◍ BGI

◍ Perkin Elmer, Inc.

◍ Pacific Biosciences of California, Inc.

◍ Bio-Rad Laboratories, Inc.

◍ Integrated DNA Technologies, Inc.

◍ RainDance Technologies, Inc.

◍ PierianDx

◍ Genomatix GmbH

◍ Macrogen, Inc.

The Targeted DNA/RNA Sequencing Market is highly competitive with key players such as Illumina, Roche, Agilent, and Thermo Fisher. These companies offer innovative sequencing technologies that provide accurate and efficient analysis of genetic material, driving market growth. Sales revenue: Illumina - $3.54B, Roche - $29.5B, Agilent - $4.91B.

Request Sample Report

Market Segmentation

By Application

◍ Human Biomedical Research

◍ Plant & Animal Sciences

◍ Drug Discovery

◍ Others

By Product

◍ DNA-based Targeted Sequencing

◍ RNA-based Targeted Sequencing

Request Sample Report

$ X Billion USD
Market Growth
Request Sample Report
THANK YOU Email : sales@reportprime.com USA : +1 507 500 7209 Website : https://www.reportprime.com/ Request Sample Report Contact US Our Clients

Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.